vs
HAEMONETICS CORP（HAE）与Inspire Medical Systems, Inc.（INSP）财务数据对比。点击上方公司名可切换其他公司
HAEMONETICS CORP的季度营收约是Inspire Medical Systems, Inc.的1.3倍（$339.0M vs $269.1M），Inspire Medical Systems, Inc.净利率更高（50.6% vs 13.2%，领先37.4%），Inspire Medical Systems, Inc.同比增速更快（12.2% vs -2.7%），HAEMONETICS CORP自由现金流更多（$87.2M vs $41.8M），过去两年Inspire Medical Systems, Inc.的营收复合增速更高（28.1% vs 0.4%）
豪洛捷（Haemonetics）是全球血液与血浆供应及服务提供商，于20世纪70年代由艾伦·（杰克）·莱瑟姆博士在马萨诸塞州内蒂克创立，业务围绕血液相关产品及配套服务展开，为全球医疗领域提供血液管理相关的专业解决方案。
Inspire Medical Systems是一家专注于阻塞性睡眠呼吸暂停治疗的医疗科技企业，研发、生产并销售植入式神经刺激设备，面向无法耐受持续气道正压通气治疗的患者，核心市场覆盖北美、欧洲及部分亚太地区，服务睡眠医学、耳鼻喉科等临床领域。
HAE vs INSP — 直观对比
营收规模更大
HAE
是对方的1.3倍
$269.1M
营收增速更快
INSP
高出15.0%
-2.7%
净利率更高
INSP
高出37.4%
13.2%
自由现金流更多
HAE
多$45.4M
$41.8M
两年增速更快
INSP
近两年复合增速
0.4%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $339.0M | $269.1M |
| 净利润 | $44.7M | $136.1M |
| 毛利率 | 59.7% | 86.6% |
| 营业利润率 | 19.9% | 17.1% |
| 净利率 | 13.2% | 50.6% |
| 营收同比 | -2.7% | 12.2% |
| 净利润同比 | 19.3% | 286.4% |
| 每股收益（稀释后） | $0.95 | $4.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HAEINSP
| Q4 25 | $339.0M | $269.1M | ||
| Q3 25 | $327.3M | $224.5M | ||
| Q2 25 | $321.4M | $217.1M | ||
| Q1 25 | $330.6M | $201.3M | ||
| Q4 24 | $348.5M | $239.7M | ||
| Q3 24 | $345.5M | $203.2M | ||
| Q2 24 | $336.2M | $195.9M | ||
| Q1 24 | — | $164.0M |
净利润HAEINSP
| Q4 25 | $44.7M | $136.1M | ||
| Q3 25 | $38.7M | $9.9M | ||
| Q2 25 | $34.0M | $-3.6M | ||
| Q1 25 | $58.0M | $3.0M | ||
| Q4 24 | $37.5M | $35.2M | ||
| Q3 24 | $33.8M | $18.5M | ||
| Q2 24 | $38.4M | $9.8M | ||
| Q1 24 | — | $-10.0M |
毛利率HAEINSP
| Q4 25 | 59.7% | 86.6% | ||
| Q3 25 | 59.5% | 85.8% | ||
| Q2 25 | 59.8% | 84.0% | ||
| Q1 25 | 58.4% | 84.7% | ||
| Q4 24 | 55.5% | 85.0% | ||
| Q3 24 | 54.2% | 84.1% | ||
| Q2 24 | 52.0% | 84.8% | ||
| Q1 24 | — | 84.9% |
营业利润率HAEINSP
| Q4 25 | 19.9% | 17.1% | ||
| Q3 25 | 17.9% | 4.3% | ||
| Q2 25 | 16.8% | -1.5% | ||
| Q1 25 | 21.6% | -0.7% | ||
| Q4 24 | 16.9% | 13.3% | ||
| Q3 24 | 15.0% | 7.0% | ||
| Q2 24 | 11.8% | 2.6% | ||
| Q1 24 | — | -9.3% |
净利率HAEINSP
| Q4 25 | 13.2% | 50.6% | ||
| Q3 25 | 11.8% | 4.4% | ||
| Q2 25 | 10.6% | -1.7% | ||
| Q1 25 | 17.5% | 1.5% | ||
| Q4 24 | 10.8% | 14.7% | ||
| Q3 24 | 9.8% | 9.1% | ||
| Q2 24 | 11.4% | 5.0% | ||
| Q1 24 | — | -6.1% |
每股收益（稀释后）HAEINSP
| Q4 25 | $0.95 | $4.57 | ||
| Q3 25 | $0.81 | $0.34 | ||
| Q2 25 | $0.70 | $-0.12 | ||
| Q1 25 | $1.17 | $0.10 | ||
| Q4 24 | $0.74 | $1.17 | ||
| Q3 24 | $0.66 | $0.60 | ||
| Q2 24 | $0.74 | $0.32 | ||
| Q1 24 | — | $-0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $363.4M | $308.3M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $911.5M | $781.2M |
| 总资产 | $2.5B | $907.3M |
| 负债/权益比越低杠杆越低 | 1.34× | — |
8季度趋势，按日历期对齐
现金及短期投资HAEINSP
| Q4 25 | $363.4M | $308.3M | ||
| Q3 25 | $296.4M | $322.6M | ||
| Q2 25 | $292.9M | $300.9M | ||
| Q1 25 | $306.8M | $369.2M | ||
| Q4 24 | $320.8M | $445.5M | ||
| Q3 24 | $299.3M | $411.0M | ||
| Q2 24 | $344.4M | $439.7M | ||
| Q1 24 | — | $441.4M |
总债务HAEINSP
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益HAEINSP
| Q4 25 | $911.5M | $781.2M | ||
| Q3 25 | $849.2M | $666.5M | ||
| Q2 25 | $882.3M | $677.8M | ||
| Q1 25 | $820.8M | $635.7M | ||
| Q4 24 | $906.9M | $689.7M | ||
| Q3 24 | $878.9M | $696.6M | ||
| Q2 24 | $905.4M | $638.1M | ||
| Q1 24 | — | $589.0M |
总资产HAEINSP
| Q4 25 | $2.5B | $907.3M | ||
| Q3 25 | $2.4B | $807.7M | ||
| Q2 25 | $2.5B | $802.2M | ||
| Q1 25 | $2.5B | $730.8M | ||
| Q4 24 | $2.5B | $808.4M | ||
| Q3 24 | $2.5B | $796.2M | ||
| Q2 24 | $2.5B | $728.4M | ||
| Q1 24 | — | $685.8M |
负债/权益比HAEINSP
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $93.6M | $52.5M |
| 自由现金流经营现金流 - 资本支出 | $87.2M | $41.8M |
| 自由现金流率自由现金流/营收 | 25.7% | 15.5% |
| 资本支出强度资本支出/营收 | 1.9% | 4.0% |
| 现金转化率经营现金流/净利润 | 2.09× | 0.39× |
| 过去12个月自由现金流最近4个季度 | $308.1M | $78.5M |
8季度趋势，按日历期对齐
经营现金流HAEINSP
| Q4 25 | $93.6M | $52.5M | ||
| Q3 25 | $111.3M | $68.5M | ||
| Q2 25 | $17.4M | $2.7M | ||
| Q1 25 | $116.6M | $-6.7M | ||
| Q4 24 | $43.8M | $69.2M | ||
| Q3 24 | $48.8M | $52.3M | ||
| Q2 24 | $-27.4M | $-78.0K | ||
| Q1 24 | — | $8.9M |
自由现金流HAEINSP
| Q4 25 | $87.2M | $41.8M | ||
| Q3 25 | $106.3M | $58.1M | ||
| Q2 25 | $13.6M | $-6.3M | ||
| Q1 25 | $100.9M | $-15.1M | ||
| Q4 24 | $35.2M | $62.2M | ||
| Q3 24 | $39.4M | $44.3M | ||
| Q2 24 | $-33.1M | $-12.5M | ||
| Q1 24 | — | $-2.8M |
自由现金流率HAEINSP
| Q4 25 | 25.7% | 15.5% | ||
| Q3 25 | 32.5% | 25.9% | ||
| Q2 25 | 4.2% | -2.9% | ||
| Q1 25 | 30.5% | -7.5% | ||
| Q4 24 | 10.1% | 25.9% | ||
| Q3 24 | 11.4% | 21.8% | ||
| Q2 24 | -9.8% | -6.4% | ||
| Q1 24 | — | -1.7% |
资本支出强度HAEINSP
| Q4 25 | 1.9% | 4.0% | ||
| Q3 25 | 1.5% | 4.6% | ||
| Q2 25 | 1.2% | 4.1% | ||
| Q1 25 | 4.7% | 4.2% | ||
| Q4 24 | 2.5% | 2.9% | ||
| Q3 24 | 2.7% | 3.9% | ||
| Q2 24 | 1.7% | 6.3% | ||
| Q1 24 | — | 7.1% |
现金转化率HAEINSP
| Q4 25 | 2.09× | 0.39× | ||
| Q3 25 | 2.88× | 6.90× | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 2.01× | -2.24× | ||
| Q4 24 | 1.17× | 1.96× | ||
| Q3 24 | 1.44× | 2.83× | ||
| Q2 24 | -0.71× | -0.01× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
INSP
暂无分部数据
